Healthcare and Life Science
Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage
FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platformNIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS TrustLondon, UK, 06 May 2026: Calla Lily Clinical Care, a women’s health-focused medical technology company, ann...
FUJIFILM Biosciences and NextCell launch new commercial platform comprised of RUO Stromal Cells and Cell Culture Media
Collaboration results in platform to help researchers overcome challenges in MSC researchNextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences ...
Beware the next generation of phishing attacks
If phishing scams are supposed to trick people, why do so many of them still feel clumsy?For years, the answer was simple: Most scams were mass-produced.The same email, the same fake website, sent to thousands of people, hoping a few would fall for it. ...
Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes
Expanded Range Increases Access to Bio-Rad’s StarBright™ Dyes for Flow Cytometry and Western Blot Applications in Immunology Research ...
Why Cambridge UK remains a global hub for antibody discovery
Cambridge UK has long been one of the world’s most important centres for life sciences, translational research and biotechnology innovation. For antibody discovery, the cluster offers a powerful combination of scientific expertise, commercial infrastructure, regulatory awareness, invest...
NGS in antibody discovery: Why sequence depth matters
Next-generation sequencing is changing how antibody discovery teams understand library performance, selection outputs and candidate diversity. Rather than relying only on small numbers of picked clones or traditional sequencing methods, NGS can provide a deeper view of how binders emerg...
Antibody discovery and IP risk: Why freedom to operate matters earlier than you think
In antibody discovery, identifying a promising binder is only part of the challenge. For well-established targets, companies also need to consider whether the resulting sequences are novel, patentable and commercially usable. Freedom-to-operate risk can become a major issue if discovery...
Unlocking hard-to-drug targets with VHH antibody discovery
Many high-value therapeutic targets remain difficult to drug, particularly where targets are intracellular, conformationally complex, poorly accessible, highly conserved or embedded in membrane environments. Traditional discovery approaches can struggle in these settings, especially whe...
Weight loss drugs boom drives pharma R&D returns, but industry could face ‘bubble’ effect
Top global pharma companies’ return on R&D increased for third consecutive year; Growth is almost entirely driven by GLP-1 drugs - used to treat obesity and diabetes - and accounts for 38% of projected sales;Obesity drugs have displaced oncology drugs as the largest contributor to t...
Whitepaper: Validating synthetic VHH libraries for therapeutic discovery
Synthetic VHH libraries are becoming an increasingly important route for antibody discovery, offering a faster, more controlled alternative to traditional immunisation-based workflows. But for drug developers, speed alone is not enough: discovery platforms must generate binders with the...